MedX’s SIAscope, a Class II A medical device, takes 5 images, including 4 spectrophotometric images 2 mm below the skin’s surface showing the disorganization of a suspicious mole or lesion. This allows dermatologists to make a more accurate assessment based on the underlying physiology of the skin. MedX is the only technology in the world that can present this additional critical imaging.
We provide rapid access to mole scanning for patients through low barrier-to-entry partners like pharmacies, physician offices, medical clinics and spas.
SIAscopy on DermSecure™ is our secure, cloud-based telemedicine platform and patient management system that seamlessly integrates with EMRs – it is where patient profiles can be created, updated and stored for up to 10 years. Our privacy policies comply with all regulations in jurisdictions in which we operate including PIPEDA, HIPAA and GDPR. We deploy the latest in security measures, engage in rigorous third-party threat testing and real-time monitoring.
Within two business days, healthcare providers and patients can access detailed assessment reports with next steps and recommendations (as required).